Aevi Genomic Medicine, Inc. (GNMX) financial statements (2022 and earlier)

Company profile

Business Address 435 DEVON PARK DRIVE,
WAYNE, PA 19087
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments12,07633,72939,83853,06433,28822,3906,431
Cash and cash equivalents12,07633,72939,83853,06433,28822,3906,431
Prepaid expense and other current assets253
Other undisclosed current assets170893335747315202286
Total current assets:12,24634,62240,17353,81133,60322,5926,970
Noncurrent Assets
Property, plant and equipment2085377424495357352
Restricted cash and investments11111123834262
Other noncurrent assets 43    
Other undisclosed noncurrent assets    9996323
Total noncurrent assets:31139388447677495737
TOTAL ASSETS:12,27734,76140,56154,25834,28023,0877,707
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2,7633,1975,4462,5862,5621,9521,473
Accounts payable1,582943137 1,076  
Employee-related liabilities471,2972,2471,5341,5611,5061,063
Other undisclosed accounts payable and accrued liabilities1,1349573,0621,052(75)446410
Other undisclosed current liabilities1,5829431371,3221,0761,062877
Total current liabilities:4,3454,1405,5833,9083,6383,0142,350
Noncurrent Liabilities
Liabilities, other than long-term debt     1,2111,931
Derivative instruments and hedges, liabilities     1,2111,931
Other undisclosed noncurrent liabilities    9804391,492
Total noncurrent liabilities:    9801,6503,423
Total liabilities:4,3454,1405,5833,9084,6184,6645,773
Stockholders' equity
Stockholders' equity attributable to parent, including:7,93230,62134,97850,35029,66218,4231,934
Common stock7644321
Additional paid in capital253,678245,593215,008188,476129,797100,12666,509
Accumulated deficit(245,753)(214,978)(180,034)(138,130)(100,138)  
Other undisclosed stockholders' equity attributable to parent     (81,705)(64,576)
Total stockholders' equity:7,93230,62134,97850,35029,66218,4231,934
TOTAL LIABILITIES AND EQUITY:12,27734,76140,56154,25834,28023,0877,707

Income statement (P&L) ($ in thousands)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Operating expenses(8,663)(34,700)(41,879)(28,398)(18,865)(17,403)(12,768)
Other undisclosed operating income (loss)(22,299)  (8,170)(74)(415)140
Operating loss:(30,962)(34,700)(41,879)(36,568)(18,939)(17,818)(12,628)
Nonoperating income (expense)187(14)(9)(1,407)51935
Investment income, nonoperating    135
Other nonoperating income (expense)187(14)(9)(1,407)518  
Loss from continuing operations before equity method investments, income taxes:(30,775)(34,714)(41,888)(37,975)(18,420)(17,815)(12,623)
Other undisclosed income (loss) from continuing operations before income taxes    (1)703(2,429)
Loss from continuing operations before income taxes:(30,775)(34,714)(41,888)(37,975)(18,421)(17,112)(15,052)
Income tax expense  (16)(17)(12)(17)(19)
Net loss attributable to parent:(30,775)(34,714)(41,904)(37,992)(18,433)(17,129)(15,071)
Other undisclosed net income available to common stockholders, basic  83,80875,98436,86617,146 
Net income (loss) available to common stockholders, basic:(30,775)(34,714)41,90437,99218,43317(15,071)
Dilutive securities, effect on basic earnings per share   824891  
Net income (loss) available to common stockholders, diluted:(30,775)(34,714)41,90438,81619,32417(15,071)

Comprehensive Income ($ in thousands)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss:(30,775)(34,714)(41,904)(37,992)(18,433)(17,129)(15,071)
Comprehensive loss, net of tax, attributable to parent:(30,775)(34,714)(41,904)(37,992)(18,433)(17,129)(15,071)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: